AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15240647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11802014 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day for 2 months
Number of subjects: 53
Study 11802014 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 53
Study 9587133 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmacytic hyperplasia (PH)
Number of subjects: 32
Study 9587133 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic PT‐LPD
Number of subjects: 32
Study 9587133 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant lymphoma/multiple myeloma (ML/MM)
Number of subjects: 32
Study 9587133 — intervention group
Group type: COMPARATOR
Intervention: Reduction in immunosuppression
Number of subjects: 32
Study 7870393 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for volume determination by SPECT (moment‐preserving bilevel thresholding and best‐fit Laplacian second derivative edge detection)
Number of subjects: 0
Study 7870393 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for volume determination by SPECT
Number of subjects: 0
Study 3130925 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 60 mg APD intravenously
Number of subjects: 30
Study 3130925 — intervention group
Group type: COMPARATOR
Intervention: Daily doses of 30 mg APD (two days) or 15 mg (four days)
Number of subjects: 30
Study 31290697 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice-based targeted medical nutrition (TMN) supplement (∼200 kcal; 10 g whey protein; ≥2.0 g eicosapentaenoic acid/docosahexaenoic acid in fish oil; and 10 μg 25-hydroxy-vitamin D3)
Number of subjects: 55
Study 31290697 — intervention group
Group type: COMPARATOR
Intervention: Milk-based isocaloric comparator
Number of subjects: 55
Study 31892700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weedy Amaranthus genotypes (A. viridis WAV7 and A. spinosus WAS13)
Number of subjects: 6
Study 31892700 — intervention group
Group type: EXPERIMENTAL
Intervention: Weedy Amaranthus genotypes
Number of subjects: 6
Study 28433366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol)
Number of subjects: 340
Study 28433366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 26452543 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE4STROKE program (8 weeks) in addition to usual care
Number of subjects: 66
Study 26452543 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (8 weeks)
Number of subjects: 66
Study 22852760 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 22852760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21865022 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 69
Study 21865022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 19181969 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgical stabilization (18 patients)
Number of subjects: 40
Study 19181969 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with orthosis (22 patients)
Number of subjects: 40
Study 19181969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17917772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue used as reinforcement on primary end-to-end esophageal anastomosis (Group A)
Number of subjects: 52
Study 17917772 — intervention group
Group type: COMPARATOR
Intervention: No fibrin glue used (Group B)
Number of subjects: 52
Study 15535794 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathic Personality Inventory (self-report instrument)
Number of subjects: 309
Study 11804384 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment approaches (surgery, radiation, chemotherapy, BSC)
Number of subjects: 0
Study 11804384 — intervention group
Group type: EXPERIMENTAL
Intervention: Future prospective randomized studies
Number of subjects: 0
Study 9440748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (pulse-intensive [PI]) treatment with dactinomycin for low-risk patients
Number of subjects: 1687
Study 9440748 — intervention group
Group type: COMPARATOR
Intervention: Divided-dose (standard [STD]) treatment with dactinomycin for low-risk patients
Number of subjects: 1687
Study 9440748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (pulse-intensive [PI]) treatment with doxorubicin for high-risk patients
Number of subjects: 1687
Study 9440748 — intervention group
Group type: COMPARATOR
Intervention: Divided-dose (standard [STD]) treatment with doxorubicin for high-risk patients
Number of subjects: 1687
Study 7919071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0
Study 7919071 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 7919071 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial-intracranial bypass surgery
Number of subjects: 0
Study 7919071 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 7919071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing trials in patients with asymptomatic bruits and other problems
Number of subjects: 0
Study 2684073 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg once daily)
Number of subjects: 186
Study 2684073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg once daily)
Number of subjects: 186
Study 2684073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Betaxolol and Chlorthalidone
Number of subjects: 186
Study 31000379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and phenylephrine nasal spray (10 mg lidocaine and 1 mg phenylephrine for children weighing 6–12 kg; 20 mg lidocaine and 2 mg phenylephrine for children weighing >12 kg)
Number of subjects: 107
Study 31000379 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride placebo nasal spray
Number of subjects: 107
Study 31000379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and phenylephrine nasal spray
Number of subjects: 107
Study 28463902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume training (HYPER)
Number of subjects: 38
Study 28463902 — intervention group
Group type: COMPARATOR
Intervention: One repetition maximum (1RM) strength test (TEST)
Number of subjects: 38
Study 25540891 — intervention group
Group type: EXPERIMENTAL
Intervention: EBO vaccine
Number of subjects: 108
Study 25540891 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR vaccine
Number of subjects: 108
Study 25540891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 108
Study 23887226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load strength training (16 weeks, 3 times a week)
Number of subjects: 23
Study 23887226 — intervention group
Group type: COMPARATOR
Intervention: Control period (16 weeks)
Number of subjects: 23
Study 21614910 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen type I (Cellerate RX powder) applied in the axillary cavity after lymphadenectomy (n = 42)
Number of subjects: 80
Study 21614910 — intervention group
Group type: COMPARATOR
Intervention: Standard lymphadenectomy without sealant (Control group, n = 38)
Number of subjects: 80
Study 20140352 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine during pregnancy (Group 1)
Number of subjects: 139
Study 20140352 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine after pregnancy (Group 2)
Number of subjects: 139
Study 20140352 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (Group 3)
Number of subjects: 139
Study 17278336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempa.DOT (TDT) chemical dot thermometer
Number of subjects: 62
Study 17278336 — intervention group
Group type: COMPARATOR
Intervention: Electronic thermometer (ETT)
Number of subjects: 62
Study 15242424 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP (4 U h(‐1)) and NE
Number of subjects: 38
Study 15242424 — intervention group
Group type: COMPARATOR
Intervention: NE alone
Number of subjects: 38
Study 11317948 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression (not thinking about the target thought)
Number of subjects: 112
Study 11317948 — intervention group
Group type: COMPARATOR
Intervention: Control condition (thinking about anything)
Number of subjects: 112
Study 11317948 — intervention group
Group type: EXPERIMENTAL
Intervention: State and trait anxiety influence
Number of subjects: 112
Study 9604230 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted LT4-dose in combination with 150 micrograms iodide (group A)
Number of subjects: 105
Study 9604230 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination of 100 micrograms LT4 plus 100 micrograms iodide (group B)
Number of subjects: 105
Study 1655350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 150 mg/die i.v. for 10 days
Number of subjects: 20
Study 1655350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1,000 mg/die i.v. for 10 days
Number of subjects: 20
Study 1655350 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. for 10 days (first study)
Number of subjects: 20
Study 1655350 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. for 10 days (second study)
Number of subjects: 20
Study 6349949 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid sigmoidoscopy
Number of subjects: 1007
Study 6349949 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 1007
Study 31529492 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV)
Number of subjects: 0
Study 31529492 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies (physician's choice with either methotrexate or bexarotene)
Number of subjects: 0
Study 27955919 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (2.0 mg/kg) administered weekly or every other week for 120 weeks
Number of subjects: 0
Study 26694733 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 3455
Study 26694733 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 3455
Study 26694733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3455
Study 26694733 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/BZA groups
Number of subjects: 3455
Study 26694733 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 3455
Study 26694733 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 3455
Study 23716986 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium hyaluronate (SH)
Number of subjects: 76
Study 23716986 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 76
Study 21309194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose 90 mg/dL or greater
Number of subjects: 1841
Study 21309194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour glucose 165 mg/dL or greater
Number of subjects: 1841
Study 21309194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour glucose 150 mg/dL or greater
Number of subjects: 1841
Study 21309194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and all postload levels
Number of subjects: 1841
Study 19132285 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine extended release (TOL ER) for 24 weeks
Number of subjects: 161
Study 17610195 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 3604
Study 17610195 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3604
Study 15268892 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg daily for 10 doses during the first 2 weeks, then once a week for 12 weeks)
Number of subjects: 324
Study 15268892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 11296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-dose administration of 60 mg dihydrocodeine
Number of subjects: 26
Study 11296884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic high-dosage administration of dihydrocodeine
Number of subjects: 26
Study 10833290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenderfoot
Number of subjects: 40
Study 10833290 — intervention group
Group type: COMPARATOR
Intervention: Lancetta
Number of subjects: 40
Study 8037259 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg p.o.)
Number of subjects: 10
Study 8037259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2906910 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAVE
Number of subjects: 22
Study 2906910 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral corticosteroids (0.3‐0.4 mg. of betamethasone disodium phosphate daily)
Number of subjects: 42
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral hydrocortisone hemisuccinate (10 mg. daily for up to three years)
Number of subjects: 42
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral betamethasone 17‐valerate (0.4 mg. per day)
Number of subjects: 42
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Synacthen (tetracosactrin) stimulation
Number of subjects: 42
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral hydrocortisone hemisuccinate and betamethasone 17‐valerate
Number of subjects: 42
Study 4309863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oral betamethasone disodium phosphate
Number of subjects: 42
Study 29105056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) after induction, 7 cmH2 O positive end‐expiratory pressure (PEEP) during anesthesia and continuous positive airway pressure (CPAP) during emergence with 0.4 inspired oxygen fraction (FiO2)
Number of subjects: 18
Study 29105056 — intervention group
Group type: COMPARATOR
Intervention: Ventilated without LRM, with 0 cmH2 O PEEP, and 1.0 FiO2 during emergence without CPAP application
Number of subjects: 18
Study 28980935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (5x10^9 cfu/capsule) for 8 weeks
Number of subjects: 80
Study 28980935 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study 25936291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad film clip
Number of subjects: 182
Study 25936291 — intervention group
Group type: COMPARATOR
Intervention: Neutral film clip
Number of subjects: 182
Study 25936291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 182
Study 23982366 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d of sofosbuvir and weight‐based ribavirin for 24 weeks
Number of subjects: 60
Study 23982366 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of sofosbuvir with weight‐based ribavirin for 24 weeks
Number of subjects: 60
Study 23982366 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of sofosbuvir with low‐dose 600 mg/d of ribavirin for 24 weeks
Number of subjects: 60
Study 21502764 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A into both orbicularis oculi and perioral muscles
Number of subjects: 23
Study 21502764 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A into orbicularis oculi and placebo into perioral muscles
Number of subjects: 23
Study 17392695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake
Number of subjects: 432
Study 17392695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake <90 mg/day
Number of subjects: 432
Study 17392695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake for <12 weeks
Number of subjects: 432
Study 16815130 — intervention group
Group type: EXPERIMENTAL
Intervention: Five meals per day
Number of subjects: 31
Study 16815130 — intervention group
Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 31
Study 12689782 — intervention group
Group type: COMPARATOR
Intervention: High-level spinal cord injury during the lift phase
Number of subjects: 11
Study 12689782 — intervention group
Group type: COMPARATOR
Intervention: High-level spinal cord injury muscular demand
Number of subjects: 11
Study 12689782 — intervention group
Group type: COMPARATOR
Intervention: Anterior deltoid muscle
Number of subjects: 11
Study 12689782 — intervention group
Group type: COMPARATOR
Intervention: Pectoralis major muscle
Number of subjects: 11
Study 10895746 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone 40 mg
Number of subjects: 95
Study 10895746 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone 20 mg
Number of subjects: 95
Study 10895746 — intervention group
Group type: COMPARATOR
Intervention: No steroid (0 mg)
Number of subjects: 95
Study 9384397 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed system drainage
Number of subjects: 257
Study 9384397 — intervention group
Group type: COMPARATOR
Intervention: Burr-hole irrigation alone
Number of subjects: 257
Study 9384397 — intervention group
Group type: COMPARATOR
Intervention: No closed system drainage
Number of subjects: 257
Study 9384397 — intervention group
Group type: COMPARATOR
Intervention: High-intensity group
Number of subjects: 257
Study 9384397 — intervention group
Group type: COMPARATOR
Intervention: Nonhigh-intensity group
Number of subjects: 257
Study 8334086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 607
Study 8334086 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 607
Study 3310826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.030 mg ethinylestradiol and 0.150 mg levonorgestrel
Number of subjects: 20
Study 3310826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.030 mg ethinylestradiol and 0.150 mg desogestrel
Number of subjects: 20
Study 3310826 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.030 mg ethinylestradiol and 0.150 mg levonorgestrel)
Number of subjects: 20
Study 3310826 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.030 mg ethinylestradiol and 0.150 mg desogestrel)
Number of subjects: 20
Study 31948767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin MDA with three consecutive daily doses of 300 μg/kg (3×300 μg/kg)
Number of subjects: 0
Study 31948767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin MDA added to seasonal malaria chemoprevention
Number of subjects: 0
Study 31948767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin MDA added to MDA with dihydroartemisinin‐piperaquine
Number of subjects: 0
Study 29338857 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer
Number of subjects: 1508
Study 29338857 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 1508
Study 27921413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose phototherapy (mixture of UVA, UVB, and visible light)
Number of subjects: 62
Study 27921413 — intervention group
Group type: COMPARATOR
Intervention: Visible light alone (placebo)
Number of subjects: 62
Study 24693926 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatment at the hospital plus a weekly session with a peer of their choice (Experimental group)
Number of subjects: 134
Study 24693926 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment at the hospital plus a weekly interactive and physical activity session (Comparison group)
Number of subjects: 134
Study 23799702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription plus referral intervention (n = 12)
Number of subjects: 35
Study 23799702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription only intervention (n = 12)
Number of subjects: 35
Study 23799702 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 11)
Number of subjects: 35
Study 21397440 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR with the Talent device
Number of subjects: 195
Study 18480190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (physical training twice weekly + cognitive-behavioral training once weekly)
Number of subjects: 209
Study 18480190 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (twice weekly)
Number of subjects: 209
Study 18480190 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (physical training + cognitive-behavioral training)
Number of subjects: 209
Study 16574438 — intervention group
Group type: EXPERIMENTAL
Intervention: NSCLC patients
Number of subjects: 21
Study 16574438 — intervention group
Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 21
Study 12707193 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 25
Study 12707193 — intervention group
Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (control)
Number of subjects: 25
Study 15321086 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. glycopyrrolate 4.0 microg/kg (group G)
Number of subjects: 40
Study 15321086 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 40
Study 9014624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (5 ml) instilled hourly for 12 h
Number of subjects: 30
Study 9014624 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (5 ml) instilled hourly for 12 h
Number of subjects: 30
Study 9014624 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of lignocaine vs saline
Number of subjects: 30
Study 1359211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplementation
Number of subjects: 96
Study 1359211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3883172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (2.5 to 5 mg every 12 hours for three doses weekly)
Number of subjects: 28
Study 3883172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31550290 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour) in predictable pain condition (PC)
Number of subjects: 56